OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Applied Clinical Trials
BOSTON, PHILADELPHIA, WINSTON-SALEM – March 18, 2015 – Clinical Ink, the pioneering provider of eSource solutions for clinical trials, today announced a merger with CentrosHealth, the ground-breaking provider of configurable mobile apps for clinical trial patient engagement and electronic patient reported outcomes (ePRO) founded by MPM Capital. The combination of Clinical Ink and CentrosHealth creates a world-class clinical trial technology platform differentiated by its ability to conduct truly ‘paperless’ clinical trials with purpose-built solutions for pharma companies, research sites, and patients.
Clinical Ink also announced that MPM Capital and F2 Ventures joined FCA Venture Partners and other existing investors to provide additional growth capital for Clinical Ink to aggressively expand operational capabilities and further development of the first truly paperless clinical trial platform. Clinical Ink additionally entered into a strategic partnership with Novartis Pharmaceuticals, as part of their Trials of the Future initiative, to help drive industry-wide adoption of fully electronic clinical trials.
“The combination of Clinical Ink and CentrosHealth backed by the deep expertise, relationships, and financial resources of MPM Capital creates a powerful opportunity to transform the clinical development business model,” said Ed Seguine, CEO of Clinical Ink. “This multi-part transaction underscores the tremendous progress we’ve made and the future potential for our combined businesses to deliver innovative technology solutions that eliminate the root causes of clinical trial inefficiency. The involvement of Novartis is a significant validation of our pioneering efforts to create a completely paperless clinical trial platform and to reduce the cost, time and complexity of clinical research.”
Strategic Fit for Clinical Ink
The merger with CentrosHealth meaningfully advances Clinical Ink’s mission to streamline clinical development with an expanded product portfolio that now includes a configurable suite of mobile patient engagement solutions that offer the following customer benefits:
Intuitive, configurable platform to quickly and easily develop/deploy mobile apps to meaningfully engage patients; study configuration time is reduced to days from months
Improve compliance, retention, and satisfaction by incorporating clinical trial activities into everyday life by using patients’ own devices, providing a more comprehensive and seamless user experience
Simple integration with remote medical devices to capture critical patient data between visits
By using CentrosHealth and SureSource, Clinical Ink’s award-winning purpose-built eSource platform for research sites, research sponsors can receive all of their data, both from the site and the patient, in real-time and can dramatically reduce the cost, time, and complexity of the clinical trial process. The Clinical Ink approach to eSource and mobile data capture has been endorsed by both FDA and EMA and is an integral component of novel ‘risk-based monitoring’ approaches to clinical research oversight.
“The CentrosHealth approach to patient engagement is based on the simple premise that patients want to actively manage their participation in clinical research,” said Jeremy Sohn, Founder/CEO of CentrosHealth. “Our platform seamlessly integrates clinical trial activities such as medication reminders, visit scheduling, activity measurements and ePRO into patients’ every-day life through personalized notifications, text messages, calendar integration, and a highly functional mobile application on their personal cellphone.”
As a result of this transaction representatives from MPM Capital and F2 Ventures will join the existing board of directors of Clinical Ink.
“The pharmaceutical industry is at an inflection point in its embrace of mobile technologies,” said Todd Foley, Managing Director MPM Capital. “The combined Clinical Ink / CentrosHealth platform delivers a truly new operating model for clinical trials of the future and represents the most compelling solution to improve the clinical trial process for sites, sponsors, CROs, and patients involved in the $50 billion annual business of conducting clinical trials.”